Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy

References

• Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-Pequignot E, Hercend T. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171:1393–405. PMID: 2187904. doi:10.1084/jem.171.5.1393.
   PubMed Web of Science ®Google Scholar
• Baixeras E, Huard B, Miossec C, Jitsukawa S, Martin M, Hercend T, Auffray C, Triebel F, Piatier-Tonneau D. Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med. 1992;176:327–37. PMID: 1380059. doi:10.1084/jem.176.2.327.
   PubMed Web of Science ®Google Scholar
• Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol. 2002;32:2255–63. PMID: 12209638. doi:10.1002/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A.
   PubMed Web of Science ®Google Scholar
• Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev. 2017;276:80–96. PMID: 28258692. doi:10.1111/imr.12519.
   PubMed Web of Science ®Google Scholar
• Huard B, Tournier M, Hercend T, Triebel F, Faure F. Lymphocyte-activation gene 3/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes. Eur J Immunol. 1994;24:3216–21. PMID: 7805750. doi:10.1002/eji.1830241246.
   PubMed Web of Science ®Google Scholar
• Prigent P, El Mir S, Dreano M, Triebel F. Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses. Eur J Immunol. 1999;29:3867–76. PMID: 10601994. doi:10.1002/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E.
   PubMed Web of Science ®Google Scholar
• Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21:503–13. PMID: 15485628. doi:10.1016/j.immuni.2004.08.010.
   PubMed Web of Science ®Google Scholar
• Huard B, Prigent P, Tournier M, Bruniquel D, Triebel F. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol. 1995;25:2718–21. PMID: 7589152. doi:10.1002/eji.1830250949.
   PubMed Web of Science ®Google Scholar
• Liu W, Tang L, Zhang G, Wei H, Cui Y, Guo L, Gou Z, Chen X, Jiang D, Zhu Y, et al. Characterization of a novel C-type lectin-like gene, LSECtin: demonstration of carbohydrate binding and expression in sinusoidal endothelial cells of liver and lymph node. J Biol Chem. 2004;279:18748–58. PMID: 14711836. doi:10.1074/jbc.M311227200.
   PubMed Web of Science ®Google Scholar
• Tang L, Yang J, Liu W, Tang X, Chen J, Zhao D, Wang M, Xu F, Lu Y, Liu B, et al. Liver sinusoidal endothelial cell lectin, LSECtin, negatively regulates hepatic T-cell immune response. Gastroenterology. 2009;137:1498–508e1–5. PMID: 19632227. doi:10.1053/j.gastro.2009.07.051.
   Web of Science ®Google Scholar
• Huang YW, Meng XJ. Identification of a porcine DC-SIGN-related C-type lectin, porcine CLEC4G (LSECtin), and its order of intron removal during splicing: comparative genomic analyses of the cluster of genes CD23/CLEC4G/DC-SIGN among mammalian species. Dev Comp Immunol. 2009;33:747–60. PMID: 19166875. doi:10.1016/j.dci.2008.12.007.
   PubMed Web of Science ®Google Scholar
• Yang J, Wang H, Wang M, Liu B, Xu H, Xu F, Zhao D, Hu B, Zhao N, Wang J, et al. Involvement of LSECtin in the hepatic natural killer cell response. Biochem Biophys Res Commun. 2016;476:49–55. PMID: 27184407. doi:10.1016/j.bbrc.2016.05.072.
   PubMed Web of Science ®Google Scholar
• Xu F, Liu J, Liu D, Liu B, Wang M, Hu Z, Du X, Tang L, He F. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. Cancer Res. 2014;74:3418–28. PMID: 24769443. doi:10.1158/0008-5472.CAN-13-2690.
   PubMed Web of Science ®Google Scholar
• Turnis ME, Andrews LP, Vignali DA. Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol. 2015;45:1892–905. PMID: 26018646. doi:10.1002/eji.201344413.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44:989–1004. PMID: 27192565. doi:10.1016/j.immuni.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Baumeister SH, Freeman GJ, Dranoff G, Sharpe AH. Coinhibitory pathways in immunotherapy for cancer. Annu Rev Immunol. 2016;34:539–73. PMID: 26927206. doi:10.1146/annurev-immunol-032414-112049.
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917–27. PMID: 22186141. doi:10.1158/0008-5472.CAN-11-1620.
   PubMed Web of Science ®Google Scholar
• Huang RY, Eppolito C, Lele S, Shrikant P, Matsuzaki J, Odunsi K. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget. 2015;6:27359–77. PMID:26318293. doi:10.18632/oncotarget.4751.
   PubMed Web of Science ®Google Scholar
• Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561. PMID: 28197366. doi:10.1080/2162402X.2016.1249561.
   PubMed Web of Science ®Google Scholar
• Nath N, Godat B, Zimprich C, Dwight SJ, Corona C, McDougall M, Urh M. Homogeneous plate based antibody internalization assay using pH sensor fluorescent dye. J Immunol Methods. 2016 Apr;431:11–21 . PMID: 26851520. doi:10.1016/j.jim.2016.02.001.
   PubMed Web of Science ®Google Scholar
• Bhagwat B, Cherwinski H, Sathe M, Seghezzi W, McClanahan TK, de Waal Malefyt R, Willingham A. Establishment of engineered cell-based assays mediating LAG3 and PD1 immune suppression enables potency measurement of blocking antibodies and assessment of signal transduction. J Immunol Methods. 2018;456:7–14. PMID: 29427592. doi:10.1016/j.jim.2018.02.003.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–54. PMID: 22658127. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Gravitz L. Cancer immunotherapy. Nature. 2013;504:S1. PMID: 24352357. doi:10.1038/504S1a.
   PubMed Web of Science ®Google Scholar
• Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11:24–37. PMID: 24247168. doi:10.1038/nrclinonc.2013.208.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, Drengler R, Chen C, Smith L, Espino G, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286–93. PMID: 25977344. doi:10.1158/1078-0432.CCR-14-2607.
   PubMed Web of Science ®Google Scholar
• Chang SS. Re: efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. J Urol. 2018;199:1110–12. PMID: 29677898. doi:10.1016/j.juro.2018.02.033.
   Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30. PMID: 25840693. doi:10.1016/S1470-2045(15)70122-1.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34. PMID: 26398076. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8. PMID: 29357948. doi:10.1186/s40425-018-0316-z.
   PubMed Web of Science ®Google Scholar
• Dempke WCM, Fenchel K, Uciechowski P, Dale SP. Second- and third-generation drugs for immuno-oncology treatment-The more the better? Eur J Cancer. 2017;74:55–72. PMID: 28335888. doi:10.1016/j.ejca.2017.01.001.
   PubMed Web of Science ®Google Scholar
• Garber K. Industry ‘road tests’ new wave of immune checkpoints. Nat Biotechnol. 2017;35:487–88. PMID: 28591107. doi:10.1038/nbt0617-487.
   PubMed Web of Science ®Google Scholar
• Qiao Y, Zhou L, Wang Y, Liu F, Xie P, Chen Y, Zhang D, Zhao X. Screening for antibodies against intact cancer cells with a naive large phage antibody library. Int J Mol Med. 2012;29:37–46. PMID: 21956702. doi:10.3892/ijmm.2011.800.
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107:7875–80. PMID: 20385810. doi:10.1073/pnas.1003345107.
   PubMed Web of Science ®Google Scholar
• Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen HR, Pyle KJ, Hipkiss E, Vignali DAA, Pardoll DM, Drake CG. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J Immunol. 2009;182:6659–69. PMID: 19454660. doi:10.4049/jimmunol.0804211.
   PubMed Web of Science ®Google Scholar
• Wierz M, Pierson S, Guyonnet L, Viry E, Lequeux A, Oudin A, Niclou SP, Ollert M, Berchem G, Janji B, et al. Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia. Blood. 2018;131:1617–21. PMID: 29439955. doi:10.1182/blood-2017-06-792267.
   PubMed Web of Science ®Google Scholar
• Sblattero D, Bradbury A Exploiting recombination in single bacteria to make large phage antibody libraries. Nat Biotechnol. 2000 Jan;18(1):75–80. PMID:10625396. doi:10.1038/71958.
   PubMed Web of Science ®Google Scholar
• Li MZ, Elledge SJ Harnessing homologous recombination in vitro to generate recombinant DNA via SLIC. Nat Methods. 2007 Mar;4(3):251–56. PMID: 17293868. doi:10.1038/nmeth1010.
   PubMed Web of Science ®Google Scholar
• Feng Y, Wang Y, Zhu Z, Li W, Sussman RT, Randall M, Bosse KR, Maris JM, Dimitrov DS Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes. MAbs. 2016 May-Jun;8(4):799–810. PMID: 26910291. doi:10.1080/19420862.2016.1155014.
   PubMed Web of Science ®Google Scholar